Casey KA, Guo X, Smith MA, *et al*. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Science, Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286

This article has been corrected since it first published. This is to inform that co-author Wendy I White's affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.
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